EBS Technologies develops software and hardware for medical stimulation therapies, notably the Eyetronic system for treating visual field loss. The non-invasive Eyetronic therapy has demonstrated both neuroprotection and neurorestoration, reportedly slowing disease progression and restoring vision in glaucoma. Its mode of action—applying gentle pulses to optic nerve cells to reactivate cell activity—is published and was the basis for a multicenter randomized controlled clinical trial. The company holds patents in the EU, Japan and the USA and received CE mark approval based on clinical trial results. EBS is based close to Berlin, Germany. It raised €3 million to accelerate growth, support international expansion and set up a US clinical trial. EBS Technologies develops software and hardware for non-invasive EBS therapy to treat visual field loss. The company has completed a clinical trial of the EBS therapy and introduced the treatment in Germany in 2014, where it is available in selected eye care clinics and therapy centers. The therapy is CE-marked and approved as a medical device under EU regulations. Led by CEO Ulf Pommerening, EBS Technologies intends to use proceeds from the current financing to accelerate market penetration, initially targeting the USA. The company raised €1.1m in a financing round that remains open to additional investors. The round was led by Earlybird and High-Tech Gründerfonds, with participation from Prof. Dr. med. Jens Ellrich and private investor Rainer Christine. EBS Technology develops a medical device aimed at treating neurological deficits resulting from stroke and brain trauma. The company’s prototype device is approved for use in clinical studies. The new funds are intended to enable the company to bring the medical device to market approval. In parallel, EBS plans to conduct further clinical trials to pursue additional indications. The company was established in 2007 and is based in Kleinmachnow, Germany. It previously received seed financing from High-Tech Gründerfonds in 2008, which supported prototype development.

Total raised

$9M

Funding rounds

3

Latest round

Equity

Latest activity

Aug 2017